Article
Vancouver-iCo Therapeutics Inc. said the FDA has accepted an investigational new drug application for iCo-007 to treat diabetic macular edema (DME).
Vancouver-iCo Therapeutics Inc. said the FDA has accepted an investigational new drug application for iCo-007 to treat diabetic macular edema (DME). The biotechnology company plans to begin its phase I clinical trial for diffuse DME during the first half of this year.
The second-generation antisense drug targets c-Raf kinase messenger RNA, potentially decreasing the edema in the retina by decreasing the signaling of various growth factors, including VEGF, which signal through the c-Raf kinase/MAP kinase pathway.
Designed and discovered by Isis Pharmaceuticals Inc., the drug was licensed to iCo Therapeutics in August 2005.
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.